Welcome to our dedicated page for NIKI BIOSOLUTIONS INC, news (Ticker: NIKI), a resource for investors and traders seeking the latest updates and insights on NIKI BIOSOLUTIONS INC, stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NIKI BIOSOLUTIONS INC,'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NIKI BIOSOLUTIONS INC,'s position in the market.
Niki BioSolutions (NIKI) announced that its subsidiary DiamiR Biosciences entered a strategic agreement to provide Apolipoprotein E (APOE) genotyping services to Progressive Medical Research (PMR) for ongoing clinical and translational research programs.
According to Niki BioSolutions, PMR will use the company’s CAP- and New York CLEP-approved testing platform and laboratory infrastructure to integrate validated APOE genetic data into clinical trial workflows, particularly in studies related to Alzheimer’s disease, cardiovascular health, and lipid metabolism. The collaboration aims to advance precision medicine and generate actionable genetic insights for Alzheimer’s research. Financial terms were not disclosed.